Terms: = Lung cancer AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12
900 results:
1. Targeted therapeutic options in early and metastatic NSCLC-overview.
Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
[TBL] [Abstract] [Full Text] [Related]
2. Precision nanomedicine to treat non-small cell lung cancer.
Dessai A; Nayak UY; Nayak Y
Life Sci; 2024 Jun; 346():122614. PubMed ID: 38604287
[TBL] [Abstract] [Full Text] [Related]
3. If it's a target, it's a pan-cancer target: Tissue is not the issue.
Adashek JJ; Kato S; Sicklick JK; Lippman SM; Kurzrock R
Cancer Treat Rev; 2024 Apr; 125():102721. PubMed ID: 38522181
[TBL] [Abstract] [Full Text] [Related]
4. Targeting ret alterations in non-small cell lung cancer.
Nishikawa G; Klein MA
Curr Probl Cancer; 2024 Apr; 49():101074. PubMed ID: 38494387
[TBL] [Abstract] [Full Text] [Related]
5. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, ret fusions and MET exon 14 skipping in NSCLC.
Melchior L; Hirschmann A; Hofman P; Bontoux C; Concha A; Mrabet-Dahbi S; Vannuffel P; Watkin E; Putzová M; Scarpino S; Cayre A; Martin P; Stoehr R; Hartmann A
Virchows Arch; 2024 Apr; 484(4):677-686. PubMed ID: 38492039
[TBL] [Abstract] [Full Text] [Related]
6. Unraveling the Promise of ret Inhibitors in Precision cancer Therapy by Targeting ret Mutations.
Wang ZX; Li QQ; Cai J; Wu JZ; Wang JJ; Zhang MY; Wang QX; Tong ZJ; Yang J; Wei TH; Zhou Y; Dai WC; Ding N; Leng XJ; Sun SL; Xue X; Yu YC; Yang Y; Li NG; Shi ZH
J Med Chem; 2024 Mar; 67(6):4346-4375. PubMed ID: 38484122
[TBL] [Abstract] [Full Text] [Related]
7. Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell lung cancer.
Yorio J; Lofgren KT; Lee JK; Tolba K; Oxnard GR; Schrock AB; Huang RSP; Brisbin L
JCO Precis Oncol; 2024 Mar; 8():e2300292. PubMed ID: 38452312
[TBL] [Abstract] [Full Text] [Related]
8. [Intraductal carcinomas of the salivary glands: a clinicopathological and molecular genetic analysis of twenty-seven cases].
Sun Q; Sun JJ; Wang M; Zhang L; Zhang XW; Wei JG; Kong LF; Li J
Zhonghua Bing Li Xue Za Zhi; 2024 Mar; 53(3):250-256. PubMed ID: 38433052
[No Abstract] [Full Text] [Related]
9. Generating Potential ret-Specific Inhibitors Using a Novel LSTM Encoder-Decoder Model.
Liu L; Zhao X; Huang X
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397034
[TBL] [Abstract] [Full Text] [Related]
10. Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions.
Rosell R; Pedraz-Valdunciel C; Jain A; Shivamallu C; Aguilar A
Expert Opin Investig Drugs; 2024 Mar; 33(3):171-182. PubMed ID: 38372666
[TBL] [Abstract] [Full Text] [Related]
11. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.
Christopoulos P
Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058
[TBL] [Abstract] [Full Text] [Related]
12. 2021 WHO Classification of lung cancer: Molecular Biology Research and Radiologic-Pathologic Correlation.
Sasaki T; Kuno H; Hiyama T; Oda S; Masuoka S; Miyasaka Y; Taki T; Nagasaki Y; Ohtani-Kim SJ; Ishii G; Kaku S; Shroff GS; Kobayashi T
Radiographics; 2024 Mar; 44(3):e230136. PubMed ID: 38358935
[TBL] [Abstract] [Full Text] [Related]
13. Efficacy of first-line treatment options beyond ret-TKIs in advanced ret-rearranged non-small cell lung cancer: A multi-center real-world study.
Ge Y; Li J; Gong W; Wang J; Wei X; Liu J; Wang S; Wang L; Sun H; Cheng Q; Sun Y; Dang Q; Sun Y; Gao A
Cancer Med; 2024 Jan; 13(2):e6960. PubMed ID: 38349001
[TBL] [Abstract] [Full Text] [Related]
14. LIBretTO-431: Is it time to reconsider randomized phase 3 trials for uncommon oncogenic drivers in non-small-cell lung cancer?
Russo A; Muscolino P; Rolfo C
Med; 2024 Feb; 5(2):112-114. PubMed ID: 38340705
[TBL] [Abstract] [Full Text] [Related]
15. Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with
Bhandari NR; Gilligan AM; Myers J; Ale-Ali A; Smolen L
J Med Econ; 2024; 27(1):348-358. PubMed ID: 38334069
[TBL] [Abstract] [Full Text] [Related]
16. Response to immune checkpoint inhibitor combination therapy in metastatic ret-mutated lung cancer from real-world retrospective data.
Yan N; Zhang H; Shen S; Guo S; Li X
BMC Cancer; 2024 Feb; 24(1):178. PubMed ID: 38317126
[TBL] [Abstract] [Full Text] [Related]
17. Upfront Multiplex Gene Test Helps Prolong Survival in Advanced Non-small Cell lung cancer.
Kanasaki H; Ozawa Y; Nakamura N; Nagasaki K; Matsuyama W; Akahori D; Niwa M; Ogasawara T; Sato J
Anticancer Res; 2024 Feb; 44(2):723-730. PubMed ID: 38307579
[TBL] [Abstract] [Full Text] [Related]
18. Malignant peritoneal mesotheliomas of rats induced by multiwalled carbon nanotubes and amosite asbestos: transcriptome and epigenetic profiles.
Reamon-Buettner SM; Rittinghausen S; Klauke A; Hiemisch A; Ziemann C
Part Fibre Toxicol; 2024 Jan; 21(1):3. PubMed ID: 38297314
[TBL] [Abstract] [Full Text] [Related]
19. [Clinicopathological features of SMARCA4-deficient lung adenocarcinoma: a study of 42 cases].
Han J; Gao XZ; Xu Y; Liu EJ; Du Q; Chen K; Li SL
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):136-142. PubMed ID: 38281780
[No Abstract] [Full Text] [Related]
20. Characteristics and Survival Outcomes of Patients With Metastatic
Hackshaw A; Fajardo O; Dafni U; Gelderblom H; Garrido P; Siena S; Taylor MH; Bordogna W; Nikolaidis C
JCO Precis Oncol; 2024 Jan; 8(1):e2300334. PubMed ID: 38271655
[TBL] [Abstract] [Full Text] [Related]
[Next]
